Page last updated: 2024-11-10

acetyldigitoxin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Acetyldigitoxins: Cardioactive derivatives of lanatoside A or of DIGITOXIN. They are used for fast digitalization in congestive heart failure. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3'''-O-acetyldigitoxin : A cardenolide glycoside compound consisting of digitoxin having an acetyl substituent at the 3-position on the D-ribo-hexopyranosyl residue at the non-reducing end. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5284512
CHEMBL ID3545057
CHEBI ID53773
SCHEMBL ID309649
MeSH IDM0000181

Synonyms (68)

Synonym
acetyldigitoxin
1111-39-3
(3beta,5beta)-3-{[3-o-acetyl-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide
adicin
digitoxin, 3'''-acetate
digitoxin, alpha-acetyl-
acylanid
alpha-acetyldigitoxins
(3beta,5beta)-3-((o-3-o-acetyl-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide
einecs 214-178-4
(3beta,5beta)-3-((o-3-o-acetyl-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide
card-20(22)-enolide, 3-((o-3-o-acetyl-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)-
acetyldigitoxinum [inn-latin]
acedigal
acetyldigitoxin [inn]
brn 0077291
acetildigitoxina [inn-spanish]
acylanide
digitoxin, acetate, alpha-
alpha-acetylgitaloxin
DB00511
acetylgitoxin
acetyldiginatin
alpha-acetyldigitoxin
digitoxin 3'''-acetate
acetyl-digitoxin-alpha
alpha-monoacetyldigitoxin
desglucolanatoside a
acylanid (tn)
D06881
acetyldigitoxin (inn)
acetyldigitoxins
acetyldigitoxinum
3'''-o-acetyldigitoxin
3beta-[3-o-acetyl-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyloxy]-14-hydroxy-5beta-card-20(22)-enolide
CHEBI:53773 ,
acetildigitoxina
[(2r,3r,4s,6s)-3-hydroxy-6-[(2r,3s,4s,6s)-4-hydroxy-6-[(2r,3s,4s,6r)-4-hydroxy-6-[[(3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2h-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methylo
unii-0zv4q4l2fu
0zv4q4l2fu ,
acetyldigitoxin [inn:nf]
gtpl6794
(3.beta.,5.beta.)-3-((o-3-o-acetyl-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide
acetyldigitoxins .alpha.-form [mi]
acetyldigitoxin [orange book]
acetyldigitoxins .alpha.-form
acetyldigitoxin [who-dd]
acetyldigitoxin [mart.]
SCHEMBL309649
CHEMBL3545057
DTXSID6022551 ,
(2r,3r,4s,6s)-3-hydroxy-6-{[(2r,3s,4s,6s)-4-hydroxy-6-{[(2r,3s,4s,6r)-4-hydroxy-6-{[(1s,2s,5s,7r,10r,11s,14r,15r)-11-hydroxy-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-5-yl]oxy}-2-methyloxan-3-yl]oxy}-2-met
C22191
EN300-24432971
(2r,3r,4s,6s)-6-{[(2r,3s,4s,6s)-6-{[(2r,3s,4s,6r)-6-{[(1r,3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-9a,11a-dimethyl-1-(5-oxo-2,5-dihydrofuran-3-yl)-hexadecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-4-hydroxy-2-methyloxan-3-yl]oxy}-4-hydroxy-2-methyloxan-3
CS-0006116
HY-16022
dtxcid001473935
acetildigitoxina (inn-spanish)
c01aa02
acetildigitossina
3beta-(3-o-acetyl-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyloxy)-14-hydroxy-5beta-card-20(22)-enolide
acetyldigitoxins alpha-form
acetyldigitoxin (mart.)
acetyldigitoxinum (inn-latin)
acetyldigitoxine
c01aa01
AKOS040750096
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
cardiotonic drugA drug that has a strengthening effect on the heart or that can increase cardiac output.
enzyme inhibitorA compound or agent that combines with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
cardenolide glycosideAny member of the class of cardenolides with glycosyl residues attached to position 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID127350Binding affinity against human monoclonal antibody (mAb)-1B32002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127349Binding affinity against human monoclonal antibody (mAb)-11E62002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127352Binding affinity against human monoclonal antibody (mAb)-7F22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127351Binding affinity against human monoclonal antibody (mAb)-5C22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (114)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990108 (94.74)18.7374
1990's4 (3.51)18.2507
2000's1 (0.88)29.6817
2010's1 (0.88)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.10 (24.57)
Research Supply Index4.80 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index53.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (3.42%)5.53%
Reviews2 (1.71%)6.00%
Case Studies5 (4.27%)4.05%
Observational0 (0.00%)0.25%
Other106 (90.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]